2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk
- PMID: 31591002
- DOI: 10.1016/j.atherosclerosis.2019.08.014
2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk
Erratum in
-
Erratum to "2019 ESC/EAS guidelines for the management of dyslipidemias: Lipid modification to reduce cardiovascular risk" [Atherosclerosis 290 (2019) 140-205].Atherosclerosis. 2020 Jan;292:160-162. doi: 10.1016/j.atherosclerosis.2019.11.020. Epub 2019 Dec 4. Atherosclerosis. 2020. PMID: 31811963 No abstract available.
-
Corrigendum to "2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk" [Atherosclerosis 290 (2019) 140-205].Atherosclerosis. 2020 Feb;294:80-82. doi: 10.1016/j.atherosclerosis.2019.12.004. Epub 2019 Dec 20. Atherosclerosis. 2020. PMID: 31870624 No abstract available.
Keywords: Apolipoprotein B; Cholesterol;; Dyslipidaemias; Familial hypercholesterolaemia; Guidelines; High-density lipoproteins; Lipoprotein remnants; Lipoprotein(a); Low-density lipoproteins; Total cardiovascular risk; Treatment (adherence); Treatment (drugs); Treatment (lifestyle); Triglycerides; Very low-density lipoproteins.
Comment in
-
The changing landscape of lipid-lowering therapy after the new ESC/EAS guidelines for the management of dyslipidaemias: Launching the era of triple hypolipidaemic therapy in very high risk patients.Atherosclerosis. 2020 Jan;292:231-233. doi: 10.1016/j.atherosclerosis.2019.11.009. Epub 2019 Nov 14. Atherosclerosis. 2020. PMID: 31784033 No abstract available.
-
Updated treatment thresholds in the 2019 ESC/EAS dyslipidaemia guidelines substantially expand indications for statin use for primary prevention at population level: Results from the Rotterdam Study.Atherosclerosis. 2020 Apr;299:64-66. doi: 10.1016/j.atherosclerosis.2020.02.020. Epub 2020 Feb 29. Atherosclerosis. 2020. PMID: 32169303 No abstract available.
-
Very high-risk familial hypercholesterolaemia patients in real life: The remaining gap in achieving the current LDL-C targets despite the use of PCSK9 inhibitors.Atherosclerosis. 2020 Sep;309:67-69. doi: 10.1016/j.atherosclerosis.2020.07.018. Epub 2020 Jul 30. Atherosclerosis. 2020. PMID: 32859385 No abstract available.
Similar articles
-
News from ESC congress 2019: New ESC/EAS guidelines for dyslipidaemia management published.Atherosclerosis. 2019 Dec;291:124-126. doi: 10.1016/j.atherosclerosis.2019.09.013. Epub 2019 Oct 5. Atherosclerosis. 2019. PMID: 31668350 No abstract available.
-
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.Eur Heart J. 2020 Jan 1;41(1):111-188. doi: 10.1093/eurheartj/ehz455. Eur Heart J. 2020. PMID: 31504418 No abstract available.
-
Dyslipidaemias in 2017: Atherogenic lipoproteins as treatment targets.Nat Rev Cardiol. 2018 Jan 16;15(2):75-76. doi: 10.1038/nrcardio.2017.221. Nat Rev Cardiol. 2018. PMID: 29336436 Review. No abstract available.
-
2018 Guidelines for the management of dyslipidemia.Korean J Intern Med. 2019 Jul;34(4):723-771. doi: 10.3904/kjim.2019.188. Epub 2019 Jul 1. Korean J Intern Med. 2019. PMID: 31272142 Free PMC article. Review. No abstract available.
-
Therapeutic inertia in lipid management among Polish adults with type 1 diabetes - results from the cross-sectional PARADISE T1DM study.Nutr Metab Cardiovasc Dis. 2025 May;35(5):103853. doi: 10.1016/j.numecd.2025.103853. Epub 2025 Jan 4. Nutr Metab Cardiovasc Dis. 2025. PMID: 39929759
Cited by
-
How will lung cancer screening and lung nodule management change the diagnostic and surgical lung cancer landscape?Eur Respir Rev. 2024 Jun 26;33(172):230232. doi: 10.1183/16000617.0232-2023. Print 2024 Apr. Eur Respir Rev. 2024. PMID: 38925794 Free PMC article. Review.
-
PCSK9 inhibition: from effectiveness to cost-effectiveness.Front Cardiovasc Med. 2024 Jun 25;11:1339487. doi: 10.3389/fcvm.2024.1339487. eCollection 2024. Front Cardiovasc Med. 2024. PMID: 38988669 Free PMC article. Review.
-
Primary prevention of cardiovascular disease: Updated review of contemporary guidance and literature.JRSM Cardiovasc Dis. 2020 Aug 26;9:2048004020949326. doi: 10.1177/2048004020949326. eCollection 2020 Jan-Dec. JRSM Cardiovasc Dis. 2020. PMID: 32994926 Free PMC article. Review.
-
Pathogenesis of multimorbidity-what is known?Z Gerontol Geriatr. 2021 Oct;54(6):590-596. doi: 10.1007/s00391-020-01752-z. Epub 2020 Jul 10. Z Gerontol Geriatr. 2021. PMID: 32651847 Free PMC article.
-
Impact of Prior Stroke on Long-Term Outcomes in Patients With Acute Coronary Syndrome.Circ Rep. 2021 Apr 9;3(5):267-272. doi: 10.1253/circrep.CR-21-0010. Circ Rep. 2021. PMID: 34007940 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical